Silence Therapeutics plc files DEF 14A

Silence Therapeutics plc will hold its 2026 Annual General Meeting on June 16, 2026, to vote on nine proposals, including the re-appointment of two directors, an advisory vote on executive compensation, and the ratification and re-appointment of PricewaterhouseCoopers LLP as auditors. Shareholders are also asked to approve the company's 2025 U.K. statutory annual accounts and directors' remuneration report, and the continued application of certain takeover protections.